{
    "url_original": "https://www.wsj.com/articles/johnson-johnson-posts-higher-quarterly-revenue-lifted-by-covid-19-vaccine-11618919123?mod=business_lead_pos3",
    "url": "johnson-johnson-posts-higher-quarterly-revenue-lifted-by-covid-19-vaccine-11618919123",
    "title": "Johnson & Johnson’s Covid-19 Vaccine Adds $100 Million to Quarterly Sales",
    "sub_head": "Vaccine now on pause amid safety concerns but could return to use Friday",
    "category_1": "Business",
    "category_2": "Earnings",
    "time": "2021-04-20 07:45:00",
    "body": "Johnson & Johnson ’s  Covid-19 vaccine contributed $100 million to the company’s sales growth in the latest quarter, as U.S. health authorities re-evaluate the vaccine during a pause amid safety concerns.<br />As vaccination campaigns help ease the pandemic’s severity, Johnson & Johnson’s results from its other business lines showed a trend toward normality compared with the tumultuous first months of 2020.<br />Johnson & Johnson’s pharmaceutical revenue grew 10% year over year. Revenue from drugs such as Darzalex, for multiple myeloma, Stelara, for inflammatory diseases, and Erleada, for prostate cancer, helped drive the improvement.<br />Revenue from medical devices grew 11%, a recovery from the early days of the pandemic when many people put off elective medical procedures. Meanwhile, sales of consumer-health products declined by 2.3% compared with the same stretch last year, when shoppers were stocking up on health supplies to prepare for coronavirus lockdowns.<br />The New Brunswick, N.J.-based company logged first-quarter revenue of $22.32 billion, compared with $20.69 billion in last year’s first quarter. Analysts’ consensus forecast was for revenue of $21.98 billion, as compiled by FactSet."
}